Affinity Asset Advisors’s Generate Biomedicines GENB Stock Holding History

Affinity Asset Advisors’s Portfolio GENB Stock Details GENB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.38M	Buy	+350,000	New	+$4.27M	0.23%	76

Other funds holding GENB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

HMC

Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return

Affinity Asset Advisors's GENB Position: Q1 2026 in Review

Affinity Asset Advisors opened a new position in Generate Biomedicines (GENB) in Q1 2026: 350,000 shares worth $4.38M. The stake represents 0.23% of the portfolio and ranks #76 among its holdings.

57 funds tracked by Wall St. Rank hold GENB as of Q1 2026.

Affinity Asset Advisors held 350,000 shares of Generate Biomedicines worth $4.38M as of Q1 2026.
Generate Biomedicines was a new Affinity Asset Advisors position in Q1 2026.
Generate Biomedicines made up 0.23% of Affinity Asset Advisors's portfolio in Q1 2026, its #76 holding.
57 funds tracked by Wall St. Rank held Generate Biomedicines as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.